Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

Glenmark Pharma to Launch Phase 1 Trial in Solid Tumors for its CD38xCD3 Bispecific Antibody GBR 1342 Based on Human Translational Data

Posted On: 2018-11-08 11:29:17

Glenmark Pharmaceuticals, a global pharmaceutical company, today announced the decision to launch a Phase 1 trial in solid tumors for its CD38xCD3 bispecific antibody GBR 1342. The decision is driven by recent findings derived from a non-interventional human study utilizing a clinically validated CANscript™ platform. GBR 1342 is based on Glenmark's proprietary BEAT® platform and simultaneously targets CD38 and the CD3 T cell co-receptor. CD38 is an antigen known to be implicated in hematological malignancies as well as some solid tumors. The company intends to file an Investigational New Drug (IND) application for GBR 1342 in solid tumors and initiate a clinical trial in 2019.

"Our work with innovative immunotherapeutics such as T cell re-directing bispecific antibodies necessitates detailed analyses to fully-understand and assess the potential opportunities presented by the candidates in our pipeline," said Kurt Stoeckli, President and Chief Scientific Officer at Glenmark Pharmaceuticals. "We are pleased to report that predictive analytics have generated new insights on response rates which inform further clinical development of GBR 1342 in a variety of solid tumor types, both as monotherapy and in combination therapy."

The decision to expand clinical development of GBR 1342 was based on a recently completed ex vivo translational study in multiple solid tumors utilizing the clinically validated CANscript™ platform, where treatment with GBR 1342 revealed predictive responses in various tumor types. CANscript™ is a completely human, autologous human tumor platform that integrates an algorithm–driven strategy to predict clinical responses. Glenmark plans to submit these data, along with findings on the mechanism of action, for presentation at upcoming scientific meetings and publication in a peer-reviewed journal. An ongoing first-in-human, open-label, Phase 1 trial of GBR 1342 in multiple myeloma (NCT03309111), is assessing the safety and tolerability of increasing doses of GBR 1342, and will also evaluate biomarkers, immunogenicity, and additional measures of disease activity.

Shares of GLENMARK PHARMACEUTICALS LTD. was last trading in BSE at Rs.656.8 as compared to the previous close of Rs. 629.35. The total number of shares traded during the day was 123892 in over 2786 trades.

The stock hit an intraday high of Rs. 661 and intraday low of 630.4. The net turnover during the day was Rs. 80811486.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Cigniti Technologies Ltd reports PAT of Rs. 49.52 crores in Q2 FY19

BLS International Services Ltd consolidated PAT up at Rs. 32.99 crores in Q2 FY19

COAL India Ltd consolidated net profit in Q2 jumps to Rs. 3084.70 crores

IZMO Ltd consolidated Q2 net profit falls to Rs. 1.78 crore

NALCO Q2 PAT jumps to Rs. 510 crores

Jindal Poly Films Ltd reports loss of Rs. 10.65 crores in Q2 FY19

Vindhya Telelinks Ltd Q2 FY19 PAT zooms to Rs. 55.74 crores

Hitech corporation Ltd Q2 net profit surges to Rs. 3.29 crores

Frontline Securities Ltd reports PAT of Rs. 1.45 crore

NACL Industries Ltd Q2 net profit lower at Rs. 5.30 crores

Bannari Amman Spinning Mills Ltd Q2 PAT climbs to Rs. 7.18 crores

Artemis Global Life Sciences Ltd reports H1 FY2019 PAT of Rs. 10 crores

Kanco Tea & Industries Ltd Q2 PAT at Rs. 7.74 crores

Permanent Magnets Ltd Q2 PAT surges to Rs. 3.45 crores

Brigade Enterprises Ltd Q2 FY19 PAT rises

Century Extrusions Ltd reports net profit in Q2 FY19

Syschem India Ltd continues to post profit in Q2 FY19

MMTC Ltd Q2 PAT jumps to Rs. 31.68 crores

Cravatex Ltd reports higher Q2 net profit of Rs. 0.75 crore

Balmer Lawrie & Co. Ltd. Q2 net profit increases to Rs. 34.42 crores

Chennai Meenakshi Multispeciality Hospital Ltd Q2 net profit drops to Rs. 0.18 crore

Roto Pumps Ltd Q2 PAT up at Rs. 2.87 crores

CSL Finance Ltd Q2 net profit higher at Rs. 5.89 crores

Rathi Bars Ltd posts PAT of Rs. 1.13 crore in Q2

Hercules Hoists Ltd Q2 net profit vaults to Rs. 5.88 crores

Loyal Textile Mills Ltd Q2 net profit zooms to Rs. 9.02 crores

Mauria Udyog Ltd reports Q2 FY19 PAT of Rs. 2.47 crores

Ravileela Granites Ltd Q2 PAT slides to Rs. 0.48 crore

Hindustan Wires Ltd reports PAT of Rs. 38.10 crores on exceptional item

OIL India Ltd Q2 PAT climbs to Rs. 862.01 crores

National Plywood Industries Ltd reports net profit of Rs. 0.20 crore in Q2

Tasty Bite Eatables Ltd Q2 net profit rises to Rs. 9.32 crores

Gulf Oil Lubricants India Ltd Q2 net profit down to Rs. 40.29 crores

Nitin Castings Ltd Q2 net profit up at Rs. 0.64 crore

Nahar Spinning Mills Ltd Q2 PAT at Rs. 25.58 crores

JK Paper Ltd Q2 FY19 PAT soars to Rs. 109.57 crores

Jyoti Ltd reports net profit of Rs. 1.33 crore in Q2

USHA Martin Ltd consolidated Q2 net profit rises to Rs. 25.27 crores

Shriram EPC Ltd Q2 PAT higher at Rs. 20.54 crores

Uttam Sugar Mills Ltd Q2 loss at Rs. 24.40 crores

Virinchi Ltd Q2 consolidated PAT surges to Rs. 16.63 crores

Suryaamba Spinning Mills Ltd Q2 net profit marginally higher at Rs. 0.77 crore

Laurel Organics Ltd Q2 FY19 net profit at Rs. 1.55 crore

Godrej Industries Ltd reports consolidated net profit of Rs. 189.54 crores in Q2 FY19

Sunflag Iron & Steel Company Ltd Q2 FY19 net profit climbs to Rs. 36.87 crores

Nahar Polyfilms Ltd Q2 net profit declines to Rs. 1.85 crore

Star Cement Ltd Q2 consolidated PAT up at Rs. 38.17 crores

Apex Frozen Foods Ltd Q2 PAT lower at Rs. 19.83 crores

UCO Bank Ltd reports loss of Rs. 1136.44 crores in Q2

Almondz Global Securities Ltd consolidated Q2 net profit up at Rs. 1.68 crore







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2018